Madrigal Pharmaceuticals (MDGL) Total Liabilities (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Total Liabilities data on file, last reported at $683.9 million in Q1 2026.

• On a quarterly basis, Total Liabilities rose 139.12% year-over-year to $683.9 million in Q1 2026; TTM through Mar 2026 was $683.9 million, a 139.12% increase from a year earlier, with the FY2025 full-year figure at $656.9 million, up 128.2% from the prior year.
• Total Liabilities for Q1 2026 stood at $683.9 million, up from $656.9 million in the prior quarter.
• Over the last five years, Total Liabilities for MDGL reached as high as $736.7 million in Q3 2025 and fell as low as $76.9 million in Q1 2022.
• Historically, Total Liabilities has averaged $299.8 million across 5 years, with a median of $235.2 million in 2023.
• Across the five-year window, Total Liabilities increased 21.97% in 2024 and surged 148.8% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $165.2 million in 2022, then surged by 42.4% to $235.2 million in 2023, then grew by 22.38% to $287.9 million in 2024, then soared by 128.2% to $656.9 million in 2025, then advanced by 4.11% to $683.9 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $683.9 million in Q1 2026, $656.9 million in Q4 2025, and $736.7 million in Q3 2025.